Menu Search
Equities

Bonesupport Holding AB

BONEX:STO

Bonesupport Holding AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)352.80
  • Today's Change6.80 / 1.97%
  • Shares traded59.35k
  • 1 Year change+111.13%
  • Beta0.9038
Data delayed at least 15 minutes, as of Nov 22 2024 11:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Bonesupport Holding AB grew revenues 79.76% from 328.82m to 591.08m. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 68.17m to a profit of 245.02m.
Gross margin92.43%
Net profit margin11.12%
Operating margin11.58%
Return on assets12.85%
Return on equity15.20%
Return on investment14.98%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Bonesupport Holding AB fell by 33.93m. Cash Flow from Investing was negative at 6.06m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 18.26m for operations while cash used for financing totalled 6.70m.
Cash flow per share1.53
Price/Cash flow per share225.20
Book value per share9.92
Tangible book value per share9.71
More ▼

Balance sheet in SEKView more

Bonesupport Holding AB has little financial risk as the capital structure does not rely on leverage.
Current ratio4.74
Quick ratio3.50
Total debt/total equity0.0227
Total debt/total capital0.0222
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.